chronos_therapeutics

Chronos Therapetics strengthens management with two new vice presidents

pharmafile | August 10, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Private biotech Chronos Therapeutics has announced two new additions to its management team; Dr Fraser Murray and Dr Timonthy Schulz-Utermoehl join the company as vice presidents.

Having both co-founded UK biotech Polleo Pharma, they now leave the company bringing a wealth of scientific management expertise forged during senior tenures at Shire, AstraZeneca and Merck.

Murray boasts over 20 years of drug discovery and early development experience across a range of areas including neurodegeneration, psychiatry, inflammation and dermatology. Schulz-Utermoehl specialises in early and late-stage discovery research and preclinical development, with 17 years in the field.

Advertisement

Dr Huw Jones, CEO of Chronos Therapeutics, commented: “We are delighted to welcome Fraser and Timothy to Chronos at a time of significant expansion of our research portfolio. They bring substantial pre-clinical development expertise to our organization and are synergistic to our recent acquisition. In particular, their experience as co-founders of Polleo will be invaluable as we advance our behavioural brain disease portfolio.”

Related Content

No items found
The Gateway to Local Adoption Series

Latest content